Table 1.

Clinical characteristics of patient population at time of randomizationa

VariablePlacebo (n = 56)50 mg/d Sulodexide (n = 56)100 mg/d Sulodexide (n = 56)200 mg/d Sulodexide (n = 55)P
a Values are mean ± SD or absolute numbers (n). ACEI, angiotensin-converting enzyme inhibitors, DM1, diabetes mellitus type 1; DM2, diabetes mellitus type 2
b Statistically significant value.
Mean age (yr)47.0 ± 12.849.0 ± 12.447.4 ± 12.146.9 ± 12.50.745
Body wt (kg)78.8 ± 14.177.8 ± 12.879.5 ± 13.979.9 ± 13.40.929
Body mass index27.7 ± 5.127.4 ± 4.326.4 ± 4.227.5 ± 4.80.536
Systolic BP (mmHg)140.9 ± 16.1139.6 ± 14.2136.1 ± 15.0139.7 ± 15.00.316
Diastolic BP (mmHg)80.7 ± 8.082.6 ± 6.682.1 ± 6.682.8 ± 8.00.672
Patients on ACEI/not on ACEI (n)30/2627/2927/2932/230.921
DM1/DM2 patients (n)30/2630/2633/2331/240.930
Duration of diabetes17.2 ± 10.416.0 ± 9.615.8 ± 8.416.2 ± 10.30.923
HbA1c (%)8.8 ± 1.58.3 ± 1.88.2 ± 1.48.4 ± 1.70.084
Serum creatinine (mmol/L)90.4 ± 22.989.2 ± 18.594.9 ± 21.293.1 ± 21.20.460
AER μg/min (log)5.10 ± 1.444.62 ± 1.214.58 ± 1.245.25 ± 1.340.013b
Macro/microalbuminuric patients (n)26/3016/4017/3928/270.027b